Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.

"Competing interests N.J.B. received grant support from Celgene and Janssen; consulting fees from Janssen, Celgene, Amgen, Sanofi, Takeda, Pfizer and Karyopharm Therapeutics; and honoraria from Celgene, Janssen, AbbVie, Amgen, Sanofi, Takeda, Karyopharm Therapeutics, GlaxoSmithKline and Genentech/Roche. C.L.C. received grant support from Takeda, Celgene and Janssen and consulting fees and honoraria from Celgene, Janssen, Pfizer and Takeda. N.S.R. received grant support from Two Seventy Bio; consulting fees and honoraria from Amgen, Bristol Myers Squibb, Celgene, Janssen, Merck, GlaxoSmithKline and Takeda; and honoraria from Research to Practice and Medscape. M.Y.L. received grant support, consultancy and honoraria from AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Janssen, Karyopharm Therapeutics, Sanofi, Seattle Genetics and Takeda. B.D. received institutional grant support from Takeda, Janssen, Angiocrine, Pfizer, Poseida, Orca Bio, Molecular Template, Bristol Myers Squibb and MEI Pharma and consulting fees from Jazz Pharmaceuticals, Arivan Research and Gamida Cell. M.S. received grant support from ADCT Therapeutics and Partner Therapeutics; consulting fees and honoraria from Bristol Myers Squibb, Seattle Genetics and Pfizer; and honoraria from GlaxoSmithKline, Bristol Myers Squibb and Amgen. M.A.D., S.J., C.B., A.S. and E.M.C. are employed by Pfizer and hold stock or stock options in Pfizer. S.T. received grant support from Amgen, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Janssen and Pfizer; consulting fees from Amgen, Bristol Myers Squibb and GlaxoSmithKline; and honoraria from Amgen, AstraZeneca, Bristol Myers Squibb, Janssen, Karyopharm Therapeutics, Pfizer, Sanofi and Takeda. A.J. received consulting fees and honoraria and holds membership on boards of directors or advisory committees for AbbVie, Amgen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Millennium, Sanofi, SkylineDx and Takeda. C.G. received grant support from Celgene; consulting fees and honoraria from Bristol Myers Squibb, Celgene and Janssen; and honoraria from Takeda. M.P.C. received grant support from Celgene and Bristol Myers Squibb and consulting fees and honoraria from Amgen, AstraZeneca, Celgene/Bristol Myers Squibb, Gilead, Janssen and Teva. M.S. received grant support from Janssen and consulting fees and honoraria from Bristol Myers Squibb, Takeda, Novartis, Karyopharm Therapeutics, Sanofi and Amgen. A.M.L. received institutional grant support from Bristol Myers Squibb, Genentech, Trillium Therapeutics, Sanofi, Pfizer and Janssen Oncology; consulting fees and honoraria from Bristol Myers Squibb, Pfizer and Trillium Therapeutics; honoraria from Bristol Myers Squibb, Genmab, Amgen and Janssen; and patents/royalties from Serametrix. M.H.T. and A.D. declare no competing interests."

"This study was funded by Pfizer. Medical writing support was provided by S. Stones of Engage Scientific Solutions and funded by Pfizer. The authors thank the patients who participated in this study as well as their caregivers, families and medical staff. Competing interests: N.J.B. received grant support from Celgene and Janssen; consulting fees from Janssen, Celgene, Amgen, Sanofi, Takeda, Pfizer and Karyopharm Therapeutics; and honoraria from Celgene, Janssen, AbbVie, Amgen, Sanofi, Takeda, Karyopharm Therapeutics, GlaxoSmithKline and Genentech/Roche. C.L.C. received grant support from Takeda, Celgene and Janssen and consulting fees and honoraria from Celgene, Janssen, Pfizer and Takeda. N.S.R. received grant support from Two Seventy Bio; consulting fees and honoraria from Amgen, Bristol Myers Squibb, Celgene, Janssen, Merck, GlaxoSmithKline and Takeda; and honoraria from Research to Practice and Medscape. M.Y.L. received grant support, consultancy and honoraria from AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Janssen, Karyopharm Therapeutics, Sanofi, Seattle Genetics and Takeda. B.D. received institutional grant support from Takeda, Janssen, Angiocrine, Pfizer, Poseida, Orca Bio, Molecular Template, Bristol Myers Squibb and MEI Pharma and consulting fees from Jazz Pharmaceuticals, Arivan Research and Gamida Cell. M.S. received grant support from ADCT Therapeutics and Partner Therapeutics; consulting fees and honoraria from Bristol Myers Squibb, Seattle Genetics and Pfizer; and honoraria from GlaxoSmithKline, Bristol Myers Squibb and Amgen. M.A.D., S.J., C.B., A.S. and E.M.C. are employed by Pfizer and hold stock or stock options in Pfizer. S.T. received grant support from Amgen, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Janssen and Pfizer; consulting fees from Amgen, Bristol Myers Squibb and GlaxoSmithKline; and honoraria from Amgen, AstraZeneca, Bristol Myers Squibb, Janssen, Karyopharm Therapeutics, Pfizer, Sanofi and Takeda. A.J. received consulting fees and honoraria and holds membership on boards of directors or advisory committees for AbbVie, Amgen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Millennium, Sanofi, SkylineDx and Takeda. C.G. received grant support from Celgene; consulting fees and honoraria from Bristol Myers Squibb, Celgene and Janssen; and honoraria from Takeda. M.P.C. received grant support from Celgene and Bristol Myers Squibb and consulting fees and honoraria from Amgen, AstraZeneca, Celgene/Bristol Myers Squibb, Gilead, Janssen and Teva. M.S. received grant support from Janssen and consulting fees and honoraria from Bristol Myers Squibb, Takeda, Novartis, Karyopharm Therapeutics, Sanofi and Amgen. A.M.L. received institutional grant support from Bristol Myers Squibb, Genentech, Trillium Therapeutics, Sanofi, Pfizer and Janssen Oncology; consulting fees and honoraria from Bristol Myers Squibb, Pfizer and Trillium Therapeutics; honoraria from Bristol Myers Squibb, Genmab, Amgen and Janssen; and patents/royalties from Serametrix. M.H.T. and A.D. declare no competing interests."